Recurrent Small Cell Lung Cancer
Current Clinical Trials
Note: Some citations in the text of this section are followed by a level of
evidence. The PDQ editorial boards use a formal ranking system to help the
reader judge the strength of evidence linked to the reported results of a
therapeutic strategy. (Refer to the PDQ summary on Levels of Evidence for more
information.)
The prognosis for patients with small cell lung cancer (SCLC) that has progressed
despite chemotherapy is exceedingly poor regardless of stage. Expected median
survival is 2 to 3 months. These patients should be considered for palliative
therapy or clinical trials. Patients who are primarily resistant to
chemotherapy, and those who have received multiple chemotherapy regimens, rarely
respond to additional treatment. Patients who have initially
responded and relapsed more than 6 months following initial treatment, however, are more
likely to respond to additional chemotherapy. While no single chemotherapy
regimen should be considered standard, those that have shown activity as second
line treatment include oral etoposide, etoposide/cisplatin,
cyclophosphamide/doxorubicin/vincristine (CAV), lomustine/methotrexate,
paclitaxel, and topotecan.[1-9][Level of evidence: 3iiiDiv] A randomized
comparison of second-line treatment with either CAV or topotecan reported no
significant difference in response rates or survival, but palliation of common
lung cancer symptoms was better with topotecan.[8][Level of evidence: 1iiC]
Some patients with intrinsic endobronchial obstructing lesions or extrinsic
compression caused by tumor have achieved successful palliation with endobronchial
laser therapy (for endobronchial lesions only) and/or brachytherapy.[10]
Expandable metal stents can be safely inserted under local anesthesia via the
bronchoscope, which results in improved symptoms and pulmonary function in patients
with malignant airways obstruction.[11] Patients with progressive
intrathoracic tumor after failing initial chemotherapy can achieve significant
tumor responses, palliation of symptoms, and short-term local control with
external-beam radiation therapy. Only the rare patient, however, will
experience long-term survival following salvage radiation therapy.[12]
Patients with central nervous system recurrences can often obtain palliation of
symptoms with radiation therapy and/or additional chemotherapy. The majority
of patients treated with radiation therapy obtain objective responses and
improvement following radiation therapy.[13] A retrospective review showed
that 43% of patients treated with additional chemotherapy at the time of central nervous system relapse respond to second-line chemotherapy.[14]
Standard treatment options:
- Palliative radiation therapy.[12]
- Salvage chemotherapy can provide some palliative benefit for patients
previously sensitive to standard chemotherapy.[2,4-9]
- Local palliation with endobronchial laser therapy, endobronchial stents,
and/or brachytherapy.[10,11]
- Clinical trials of phase I or phase II drugs.
Current Clinical Trials
Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent small cell lung cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.
General information about clinical trials is also available from the NCI Web site.
References
-
Greco FA: Treatment options for patients with relapsed small cell lung cancer. Lung Cancer 9(Suppl 1): s85-s89, 1993.
-
Johnson DH, Greco FA, Strupp J, et al.: Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. J Clin Oncol 8 (10): 1613-7, 1990.
[PUBMED Abstract]
-
Spiro SG, Souhami RL, Geddes DM, et al.: Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59 (4): 578-83, 1989.
[PUBMED Abstract]
-
Evans WK, Osoba D, Feld R, et al.: Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3 (1): 65-71, 1985.
[PUBMED Abstract]
-
Sekine I, Nishiwaki Y, Kakinuma R, et al.: Late recurrence of small-cell lung cancer: treatment and outcome. Oncology 53 (4): 318-21, 1996 Jul-Aug.
[PUBMED Abstract]
-
Chute JP, Kelley MJ, Venzon D, et al.: Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer. Chest 110 (1): 165-71, 1996.
[PUBMED Abstract]
-
Ardizzoni A, Hansen H, Dombernowsky P, et al.: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (5): 2090-6, 1997.
[PUBMED Abstract]
-
von Pawel J, Schiller JH, Shepherd FA, et al.: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (2): 658-67, 1999.
[PUBMED Abstract]
-
Smit EF, Fokkema E, Biesma B, et al.: A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 77 (2): 347-51, 1998.
[PUBMED Abstract]
-
Miller JI Jr, Phillips TW: Neodymium:YAG laser and brachytherapy in the management of inoperable bronchogenic carcinoma. Ann Thorac Surg 50 (2): 190-5; discussion 195-6, 1990.
[PUBMED Abstract]
-
Wilson GE, Walshaw MJ, Hind CR: Treatment of large airway obstruction in lung cancer using expandable metal stents inserted under direct vision via the fibreoptic bronchoscope. Thorax 51 (3): 248-52, 1996.
[PUBMED Abstract]
-
Ochs JJ, Tester WJ, Cohen MH, et al.: "Salvage" radiation therapy for intrathoracic small cell carcinoma of the lung progressing on combination chemotherapy. Cancer Treat Rep 67 (12): 1123-6, 1983.
[PUBMED Abstract]
-
Carmichael J, Crane JM, Bunn PA, et al.: Results of therapeutic cranial irradiation in small cell lung cancer. Int J Radiat Oncol Biol Phys 14 (3): 455-9, 1988.
[PUBMED Abstract]
-
Kristensen CA, Kristjansen PE, Hansen HH: Systemic chemotherapy of brain metastases from small-cell lung cancer: a review. J Clin Oncol 10 (9): 1498-502, 1992.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |